Inflammation is associated with adverse cardiovascular events. Data from recent trials suggest that colchicine reduces the risk of cardiovascular events. In this multicenter trial with a 2-by-2 ...

“When we saw the data, we were surprised that there was no effect.” He no longer believes that colchicine works and has stopped prescribing it. Sanjit S. Jolly, MD, MSc Other cardiologists ...

Any cardiovascular protection from colchicine in heart attack survivors seemed to be debunked with a better-powered ...

For patients with stable coronary artery disease, colchicine conferred lower total plaque volume as measured by coronary CT angiography vs. placebo. There was no effect on volume of low ...

The FDA approved colchicine (Lodoco) for cardiovascular prevention in adults with established atherosclerotic disease or multiple risk factors, making it the first anti-inflammatory medicine with ...

BASEL, SWITZERLAND — The anti-inflammatory agent colchicine failed to show significant benefit in the treatment of patients with non-cardioembolic ischemic stroke in the primary analysis of the ...

At a median follow-up of three years, the composite of cardiovascular death, recurrent MI, stroke, or ischemia driven revascularization was not significantly different between the colchicine and ...

That's the suggestion of a new study finding that older adults who used the drug -- called colchicine -- were less likely to need hip or knee replacement surgery over the next two years ...

Colchicine fails to improve knee pain, function, or size of synovial effusions with painful knee osteoarthritis (OA), according to a study presented at the annual meeting of the American College ...